InfaCare Pharmaceutical Corporation

Stanate hyperbilirubinemia treatment awarded novel process patent

Published in Drug Law Weekly, January 4th, 2005

InfaCare Pharmaceutical Corporation announced that Stanate, its late stage drug for the treatment of hyperbilirubinemia associated with jaundice in babies, had been awarded a novel process patent (US 6,818,763) by the U.S. Patent and Trademark Office.

The new synthesis process provides for a novel approach affording lower costs due to fewer steps and increased yields.

The patent was granted to WellSpring Pharmaceutical Corporation, holder of worldwide rights to the product, who in turn has licensed commercial rights to InfaCare. The patent provides a period of coverage of 20 years.

Stanate is an investigational drug in late stage...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Law Weekly

Source: Drug Law Weekly (2005-01-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry